COST OF BONE-MARROW TRANSPLANTS IN ACUTE MYELOID LEUKÆMIA

@article{Kay1980COSTOB,
  title={COST OF BONE-MARROW TRANSPLANTS IN ACUTE MYELOID LEUK{\aE}MIA},
  author={H. E. Kay and Sylvia D. Lawler and Ray L. Powles and Hugh M. Clink},
  journal={The Lancet},
  year={1980},
  volume={315},
  pages={1067-1069}
}
View on Elsevier
doi.org
24 Citations

24 Citations

Citation Type

Citation Type

Economic burden associated with acute myeloid leukemia treatment
TLDR
AML appears to be associated with significant direct economic costs, but more studies are needed to fully assess the economic impact especially in relation to total and indirect costs.
Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
TLDR
There is very limited evidence on relative costs and cost-effectiveness of allogeneic SCT in adults with AML (DPs 1 and 2), and most reviews appeared to have omitted an appreciable proportion of potentially available evidence.
Early bone marrow transplantation in acute leukemia
TLDR
13 patients who underwent BMT for AML during first complete remission are following and all are alive without maintenance therapy and without any evidence of leukemic recurrence.
Predicting C osts o f S tem-Cell T ransplantation
TLDR
The association between clinical complications and higher costs suggests that prevention may have significant economic benefits and interventions that decrease these complications may have favorable cost-benefit ratios even if they do not affect overall survival.
Predicting costs of stem-cell transplantation.
  • S. Lee, N. Klar, J. Weeks, J. Antin
  • Medicine, Political Science
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
The association between clinical complications and higher costs suggests that prevention may have significant economic benefits and interventions that decrease these complications may have favorable cost-benefit ratios even if they do not affect overall survival.
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.
  • D. Blaise, M. Kuentz, M. Michallet
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
It is established that allogeneic BCT results in quicker hematologic recovery but is associated with a higher occurrence of chronic graft-versus-host disease.
The True Cost of Bone Marrow Transplantation
TLDR
Bone marrow transplantation is much more costly "up" "front" but perhaps not more costly long-term than alternative therapies, although economic analyses appear relatively simple, interpretation and use can be problematic.
The true cost of bone marrow transplantation.
Costs over time in conventional treatment of acute myeloid leukaemia: A study exploring changes in treatment strategies over two decades
TLDR
The aim was to analyse the consumption of different items in conventional treatment of acute myeloid leukaemia and their cost, in order to evaluate the economic consequences of new treatment strategies.
Treating acute leukaemias--a venture into economic uncertainty? A method for estimating the cost of treating patients with acute myelocytic leukaemia.
TLDR
The objective of this paper is to report a method for estimating the cost of treating acute myelocytic leukaemia (AML), based on individual data from 54 patients treated with aggressive induction courses of chemotherapy, which led to longer survival for patients who survived the initial period.
...
1
2
3
...

References

SHOWING 1-4 OF 4 REFERENCES
THE PLACE OF BONE-MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKÆMIA
Current status of bone marrow transplantation in acute leukemia.
Marrow transplantation for acute nonlymphoblastic leukemia in first remission.
TLDR
This work has reported the application of this approach combined with intensive chemotherapy treatment for bone marrow transplantation without regard to marrow toxicity in patients with central giant cell granuloma.
Cost analysis of leukemia treatment. A problem‐oriented approach
TLDR
By extending the POMR into the area of medical reimbursement with a POLC, charge incurring activities can be coupled to the results of patient care, and cost data be appropriately interpreted.